RedShift BioAnalytics, Inc. Completes $11.0 million Series C Financing
Financing to Drive Commercialization of Next Generation Biotechnology Instrumentation for Drug Discovery and Development BURLINGTON, MA – March 13, 2017 – RedShift BioAnalytics, Inc., an innovative provider of bioanalytical instrumentation for the research, development and manufacturing of protein therapeutic drugs, today announced the closing of the Company’s $11.0 million Series C Preferred Stock financing. The... Read more